GB9910934D0 — Chemical compounds
Assigned to Research Institute for Medicine and Chemistry Inc · Expires 1999-07-14 · 27y expired
What this patent protects
Formula (I) in which: R<SUP>1 </SUP>and R<SUP>2</SUP>, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R<SUP>3 </SUP>represents a methyl group having alpha- or beta-configuration; R<SUP>4 </…
USPTO Abstract
Formula (I) in which: R<SUP>1 </SUP>and R<SUP>2</SUP>, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R<SUP>3 </SUP>represents a methyl group having alpha- or beta-configuration; R<SUP>4 </SUP>represents a hydrogen atom or an etherifying or esterifying group; R<SUP>5 </SUP>represents a hydrogen atom, a hydroxyl group or a lower alkoxy group; X represents a group OR<SUP>4</SUP>, or a group NR<SUP>6</SUP>R<SUP>7 </SUP>wherein R<SUP>6 </SUP>represents a hydrogen atom, an aliphatic or araliphatic group, or an acyl group comprising an aliphatic, araliphatic or aryl group linked to the nitrogen atom by way of a carbonyl group; and R<SUP>7 </SUP>is a hydrogen atom or a lower alkyl group; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; exhibit potent effects on modulation of cell growth and differentiation, while having low calcaemic activity.
Drugs covered by this patent
- Kybella (DEOXYCHOLIC ACID) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.